N/A N=126 Evaluation of Toric Soft Contact Lenses Containing a Chromophore to Block High-Energy Visible Light
Visual Acuity
Primary: CLUE Comfort Score — 63.50; 65.28 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 Gut Decontamination In Pediatric Allogeneic Hematopoietic
Hematopoietic Stem Cell Transplantation (HSCT) · Acute GVH Disease
Primary: Gut Microbiome Description — 2.4; 3.1 Shannon diversity index
Phase 2 N=31 Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis
Brain Metastasis
Primary: Number of Participants With Symptomatic Radiation Necrosis — 1 Participants
Phase 2 N=81 Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure
COVID-19
Primary: Change in Oxygenation — 56.4; 20.6; 123.5; 83.7 mmHg
Phase 1 N=50 Multiple Ascending Dose Study of AMG 598 in Adults With Obesity
Obesity
Primary: Number of Participants With Treatment-emergent Adverse Events — 1; 6; 4; 7 Participants
Phase 3 N=691 A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer · Metastatic Colon Cancer
Primary: Overall Survival (OS) — 7.4; 4.8 months — p=< .001
Phase 3 N=590 Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months Postoperative — -8.40; -8.48; -7.69; -8.35 mmHg
Phase 2 N=20 Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Prostate Cancer
Primary: Phase Ib: Percentage of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0 percentage of participants
Phase 2 N=53 A Novel Human Lab Model for Screening AUD Medications
Alcohol Use Disorder
Primary: Percentage of Days Abstinent — 80.59; 75.62; 77.59 percent days
Phase 3 N=491 A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
Cutaneous Common Warts
Primary: The Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy…
N/A N=272 Mobile Technology to Extend Clinic-based Counseling for HIV+s in Uganda
Alcohol Use, Unspecified · HIV/AIDS
Primary: Change in Alcohol Use Measured by Self Report — 2.9; 3.0; 5.5; 2.2 drinking days — p=<0.001
Phase 3 N=521 A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Haemoglobin (HbA1c) — -1.1; -1.5; -1.6; -0.2 Percentage of HbA1c — p=<0.0001
Phase 2 N=89 Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Breast Cancer
Primary: Phase 1b: Participants Experiencing DLT — 0 Participants
Phase 1 N=128 A Study of TAK-951 in Healthy Adults
Healthy Volunteers
Primary: Parts 1 and 3: Percentage of Participants With Clinically Significant Physical Examination Findings — 0; 0; 0; 0 percentage of participants
N/A N=180 Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Primary: Number of Patients' Rheumatologists Using SLE@Duke — 16; 30 Participants — p=<0.0001